Last Updated : August 30, 2023
Details
Generic Name:
bimekizumab
Project Status:
Pending
Therapeutic Area:
Ankylosing spondylitis
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0809-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of patients with active ankylosing spondylitis.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of patients with active ankylosing spondylitis.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : August 30, 2023